Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial | Synapse
March 3, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Key Points
Switching to fixed-dose doravirine and islatravir maintains viral suppression in patients with HIV-1.
After 48 weeks, 98% of patients achieved viral load below 50 copies/mL on fixed-dose therapy.
This multicentre, randomised, open-label trial indicates its effectiveness compared to existing regimens.
Finding alternative dosing may simplify treatment for virologically suppressed adults, enhancing adherence.